LONDON/COPENHAGEN, June 23 (Reuters) - Shares in Novo Nordisk (NOVOb.CO), opens new tab fell as much ... weekend that showed no safety issues in a mid-stage trial of its oral weight-loss candidate ...

Separately, Novo Nordisk presented early data for its oral amycretin program. In Phase I and Ib/IIa trials, amycretin ...

Presenting results from the REDEFINE 1 and REDEFINE 2 studies at the American Diabetes Association (ADA) congress in Chicago, ...

Danish drugmaker Novo Nordisk has released fresh clinical data on two of its lead investigational assets, seeking to bolster ...